Protein may help identify breast cancers resistant to targeted drugs - study

Protein may help identify breast cancers resistant to targeted drugs - study

In more than 400 patients' breast cancer biopsy samples, the researchers found CDK1 activity rose as the cancer became more aggressive, and higher activity was linked to worse outcomes.

Tracking a protein that drives cell division could help doctors tell which breast cancers are likely to respond to CDK4/6 inhibitors, a widely used class of targeted drugs, an Australian study has found.

Researchers at Australia's Garvan Institute of Medical Research found that the activity of a protein called CDK1 in breast cancers is linked to how they respond to a common therapy, an insight that could inform more personalised treatment approaches for patients, according to a statement from the institute released on Friday.

The study focused on estrogen receptor-positive (ER+) breast cancer, the most common type, fueled by the hormone estrogen. Many people with this cancer now receive drugs called CDK4/6 inhibitors alongside hormone therapy.

These drugs stop cancer cells from multiplying, but they don't work for everyone, and in advanced cancer, they eventually stop working for most patients.

In more than 400 patients' breast cancer biopsy samples, the researchers found CDK1 activity rose as the cancer became more aggressive, and higher activity was linked to worse outcomes.

The findings need to be tested in larger groups of patients treated with CDK4/6 inhibitors and could eventually open the door to new drugs targeting CDK1, according to the study published in Advanced Science.

Latest Stories

• African countries face rising economic risks: six ways they can navigate global uncertainty
• How African universities can drive social change beyond teaching and research
• Smuggling, power, profit: Irregular migration out of eastern Libya
• PM Abiy Ahmed puts Ethiopian ministers through military training